ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 原著論文

Impressive Suppression of Colon Cancer Growth by Triple Combination SN38/EF24/Melatonin: "Oncogenic" Versus "Onco-Suppressive" Reactive Oxygen Species.

https://repo.qst.go.jp/records/48516
https://repo.qst.go.jp/records/48516
37543f8b-ae9e-4830-8908-5e3f99a74a23
Item type 学術雑誌論文 / Journal Article(1)
公開日 2018-02-15
タイトル
タイトル Impressive Suppression of Colon Cancer Growth by Triple Combination SN38/EF24/Melatonin: "Oncogenic" Versus "Onco-Suppressive" Reactive Oxygen Species.
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
著者 BAKALOVA, RUMIANA

× BAKALOVA, RUMIANA

WEKO 487681

BAKALOVA, RUMIANA

Search repository
ZHELEV, ZHIVKO

× ZHELEV, ZHIVKO

WEKO 487682

ZHELEV, ZHIVKO

Search repository
SAYAKA, SHIBATA

× SAYAKA, SHIBATA

WEKO 487683

SAYAKA, SHIBATA

Search repository
NIKOLOVA, BILIANA

× NIKOLOVA, BILIANA

WEKO 487684

NIKOLOVA, BILIANA

Search repository
AOKI, ICHIO

× AOKI, ICHIO

WEKO 487685

AOKI, ICHIO

Search repository
HIGASHI, TATSUYA

× HIGASHI, TATSUYA

WEKO 487686

HIGASHI, TATSUYA

Search repository
バカロバ ルミアナ

× バカロバ ルミアナ

WEKO 487687

en バカロバ ルミアナ

Search repository
柴田 さやか

× 柴田 さやか

WEKO 487688

en 柴田 さやか

Search repository
青木 伊知男

× 青木 伊知男

WEKO 487689

en 青木 伊知男

Search repository
東 達也

× 東 達也

WEKO 487690

en 東 達也

Search repository
抄録
内容記述タイプ Abstract
内容記述 Background/Aim: The study aimed to investigate the effect of multi-targeted combinations (SN38/EF24; SN38/EF24/melatonin) on the growth of colon cancer in experimental animals and their impact on the ratio “oncogenic”/“onco-suppressive” reactive oxygen species (ROS) – a crucial factor for triggering carcinogenesis, as well as for development of effective therapeutic strategies. Materials and Methods: The experiments were conducted on colon cancer-grafted mice – non-treated, SN38/EF24-treated and SN38/EF24/melatonin-treated within 22 days. The balance between different types of ROS was measured in vivo by nitroxide-enhanced magnetic resonance imaging (MRI), as well as on isolated tissue specimens by conventional analytical tests. Results: Both combinations significantly suppressed the tumor growth. Impressive anticancer effect was observed in SN38/EF24/melatonin-treated mice – almost complete destruction of the tumor. Both types of ROS (superoxide and hydroperoxides) were elevated in cancer, but the MRI data suggest that the ratio between them tends towards superoxide. SN38/EF24 decreased the level of superoxide, but did not affect the level of hydroperoxides in the cancerous tissue, while SN38/EF24/melatonin decreased the level of superoxide below the control and increased significantly the level of hydroperoxides. Conclusion: The most important observations are that: (i) colon cancer was characterized by a vicious cycle, that ensures a permanent domination of “oncogenic” ROS (as superoxide) over “onco-suppressive” ROS (as hydrogen peroxide); (ii) the anticancer effect of the triple combination EF24/SN38/melatonin was accompanied by decreasing “oncogenic” and increasing “onco-suppressive” ROS; (iii) the ratio between both types of ROS could be a new onco-target for combined therapy; and (iv) nitroxide-enhanced MRI is a valuable tool for analyzing of this ratio.
書誌情報 Anticancer research

巻 37, 号 10, p. 5449-5458, 発行日 2017-10
PubMed番号
識別子タイプ PMID
関連識別子 28982855
DOI
識別子タイプ DOI
関連識別子 10.21873/anticanres.11973
関連サイト
識別子タイプ URI
関連識別子 http://ar.iiarjournals.org/content/37/10/5449.abstract
関連名称 http://ar.iiarjournals.org/content/37/10/5449.abstract
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 23:27:17.137759
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3